The potential mechanism is that SCFAs function as histone deacetylase (HDAC) inhibitors, modulating the intestinal inflammatory response by blocking cell cycle progression and promoting the induction of apoptosis, which ultimately reduces the proliferation of tumor cells, thus exerting a positive effect on colorectal cancer treatment [197]. Here, HDAC9 is linked to colorectal cancer.